FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034126502> ?p ?o ?g. }

• W3034126502 endingPage "513" @default.
• W3034126502 startingPage "505" @default.
• W3034126502 abstract "BACKGROUND Massive transfusion protocols to treat postinjury hemorrhage are based on predefined blood product transfusion ratios followed by goal-directed transfusion based on patient's clinical evolution. However, it remains unclear how these transfusion ratios impact patient outcomes over time from injury. METHODS The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) is a phase 3, randomized controlled trial, across 12 Level I trauma centers in North America. From 2012 to 2013, 680 severely injured patients required massive transfusion. We used semiparametric machine learning techniques and causal inference methods to augment the intent-to-treat analysis of PROPPR, estimating the dynamic relationship between transfusion ratios and outcomes: mortality and hemostasis at different timepoints during the first 24 hours after admission. RESULTS In the intention-to-treat analysis , the 1:1:1 group tended to have decreased mortality, but with no statistical significance. For patients in whom hemostasis took longer than 2 hours, the 1:1:1 ratio was associated with a higher probability of hemostasis, statistically significant from the 4 th hour on. In the per-protocol, actual-transfusion-ratios-received analysis, during four successive time intervals, no significant association was found between the actual ratios and mortality. When comparing patient groups who received both high plasma/PRBC and high platelet/PRBC ratios to the group of low ratios in both, the relative risk of achieving hemostasis was 2.49 (95% confidence interval, 1.19–5.22) during the third hour after admission, suggesting a significant beneficial impact of higher transfusion ratios of plasma and platelets on hemostasis. CONCLUSION Our results suggest that the impact of transfusion ratios on hemostasis is dynamic. Overall, the transfusion ratios had no significant impact on mortality over time. However, receiving higher ratios of platelets and plasma relative to red blood cells hastens hemostasis in subjects who have yet to achieve hemostasis within 3 hours after hospital admission. LEVEL OF EVIDENCE Therapeutic IV." @default.
• W3034126502 created "2020-06-12" @default.
• W3034126502 creator A5003331076 @default.
• W3034126502 creator A5008530627 @default.
• W3034126502 creator A5013304554 @default.
• W3034126502 creator A5019303744 @default.
• W3034126502 creator A5024576216 @default.
• W3034126502 creator A5032275725 @default.
• W3034126502 creator A5045934923 @default.
• W3034126502 creator A5056060130 @default.
• W3034126502 creator A5056213580 @default.
• W3034126502 creator A5081036923 @default.
• W3034126502 creator A5088025757 @default.
• W3034126502 date "2020-06-10" @default.
• W3034126502 modified "2023-10-12" @default.
• W3034126502 title "Dynamic impact of transfusion ratios on outcomes in severely injured patients: Targeted machine learning analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios randomized clinical trial" @default.
• W3034126502 cites W1493006911 @default.
• W3034126502 cites W1729719515 @default.
• W3034126502 cites W1967433109 @default.
• W3034126502 cites W1977331361 @default.
• W3034126502 cites W1983515167 @default.
• W3034126502 cites W1986562256 @default.
• W3034126502 cites W1996710781 @default.
• W3034126502 cites W2023292526 @default.
• W3034126502 cites W2024526916 @default.
• W3034126502 cites W2033971296 @default.
• W3034126502 cites W2055315513 @default.
• W3034126502 cites W2056645952 @default.
• W3034126502 cites W2083005745 @default.
• W3034126502 cites W2084280207 @default.
• W3034126502 cites W2092158875 @default.
• W3034126502 cites W2093238685 @default.
• W3034126502 cites W2108856858 @default.
• W3034126502 cites W2121211837 @default.
• W3034126502 cites W2129551854 @default.
• W3034126502 cites W2133226878 @default.
• W3034126502 cites W2164971739 @default.
• W3034126502 cites W2561982390 @default.
• W3034126502 cites W2756604053 @default.
• W3034126502 cites W2772444304 @default.
• W3034126502 cites W2908754214 @default.
• W3034126502 cites W2974933246 @default.
• W3034126502 cites W3023771142 @default.
• W3034126502 doi "https://doi.org/10.1097/ta.0000000000002819" @default.
• W3034126502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7830749" @default.
• W3034126502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32520897" @default.
• W3034126502 hasPublicationYear "2020" @default.
• W3034126502 type Work @default.
• W3034126502 sameAs 3034126502 @default.
• W3034126502 citedByCount "11" @default.
• W3034126502 countsByYear W30341265022021 @default.
• W3034126502 countsByYear W30341265022022 @default.
• W3034126502 countsByYear W30341265022023 @default.
• W3034126502 crossrefType "journal-article" @default.
• W3034126502 hasAuthorship W3034126502A5003331076 @default.
• W3034126502 hasAuthorship W3034126502A5008530627 @default.
• W3034126502 hasAuthorship W3034126502A5013304554 @default.
• W3034126502 hasAuthorship W3034126502A5019303744 @default.
• W3034126502 hasAuthorship W3034126502A5024576216 @default.
• W3034126502 hasAuthorship W3034126502A5032275725 @default.
• W3034126502 hasAuthorship W3034126502A5045934923 @default.
• W3034126502 hasAuthorship W3034126502A5056060130 @default.
• W3034126502 hasAuthorship W3034126502A5056213580 @default.
• W3034126502 hasAuthorship W3034126502A5081036923 @default.
• W3034126502 hasAuthorship W3034126502A5088025757 @default.
• W3034126502 hasBestOaLocation W30341265022 @default.
• W3034126502 hasConcept C126322002 @default.
• W3034126502 hasConcept C141071460 @default.
• W3034126502 hasConcept C168563851 @default.
• W3034126502 hasConcept C204243189 @default.
• W3034126502 hasConcept C2776689292 @default.
• W3034126502 hasConcept C2777396833 @default.
• W3034126502 hasConcept C2778589496 @default.
• W3034126502 hasConcept C2780014101 @default.
• W3034126502 hasConcept C42219234 @default.
• W3034126502 hasConcept C44249647 @default.
• W3034126502 hasConcept C71924100 @default.
• W3034126502 hasConcept C82789193 @default.
• W3034126502 hasConcept C89560881 @default.
• W3034126502 hasConceptScore W3034126502C126322002 @default.
• W3034126502 hasConceptScore W3034126502C141071460 @default.
• W3034126502 hasConceptScore W3034126502C168563851 @default.
• W3034126502 hasConceptScore W3034126502C204243189 @default.
• W3034126502 hasConceptScore W3034126502C2776689292 @default.
• W3034126502 hasConceptScore W3034126502C2777396833 @default.
• W3034126502 hasConceptScore W3034126502C2778589496 @default.
• W3034126502 hasConceptScore W3034126502C2780014101 @default.
• W3034126502 hasConceptScore W3034126502C42219234 @default.
• W3034126502 hasConceptScore W3034126502C44249647 @default.
• W3034126502 hasConceptScore W3034126502C71924100 @default.
• W3034126502 hasConceptScore W3034126502C82789193 @default.
• W3034126502 hasConceptScore W3034126502C89560881 @default.
• W3034126502 hasIssue "3" @default.
• W3034126502 hasLocation W30341265021 @default.
• W3034126502 hasLocation W30341265022 @default.
• W3034126502 hasLocation W30341265023 @default.
• W3034126502 hasLocation W30341265024 @default.
• W3034126502 hasOpenAccess W3034126502 @default.

• next